Reckitt no longer in the running for the pole the general public of Pfizer

(Reuters) – Reckitt Benckiser (LON:RB) Group announced Wednesday that it had put an end to discussions with the pharmaceutical group Pfizer (NYSE:PFE) regarding the purchase of its products unit of health and hygiene general public.

The output of Reckitt strengthens the position of the laboratory british GlaxoSmithKline, according to sources close to the matter, was working on an offer.

It is possible that Pfizer will receive more bids by the deadline of Thursday for their presentation, added the sources.

“The acquisition of all of the products unit of health and hygiene, general public, Pfizer did not meet our purchase criteria and a partial acquisition was not possible,” explained the british-based group of consumer products.

He added that the priority remained organic growth and the integration of Mead Johnson Nutrition.

“Pfizer continues to evaluate strategic alternatives, if any, for this segment, that is to say, a demerger, a sale or any other transaction, and finally the keep; we have not yet taken a decision but we still believe in to take a in 2018”, said Pfizer.

The american laboratory hope to get a twenty billion dollars from the sale of this segment, which includes, among others, the analgesic Advil, according to sources.

(Greg Roumeliotis and Carl O’donnell in New York; Martinne Geller and Ben Hirschler in London, Manas Mishra and Rama Venkat Raman in Bangalore,; Wilfrid Exbrayat for the French service)